Immunogen (IMGN) Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. KBH
3. FDX
4. HTZ
5. HON
6. HONA
7. HELP
8. GDYN
9. NKE
10. TTWO

Go back to Immunogen (IMGN) Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

November 30, 2021 6:30 AM EST

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%

Median Duration of Response at Data Cutoff is 5.9 Months

Continued Demonstration of Favorable Tolerability Profile

BLA Submission on Track for First Quarter of 2022

Conference Call to be Held at 8:00 a.m. ET Today

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq:... More